Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 49

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
otox TherapeuticUnited States$723 $611 18.2 %18.2 %International143 137 4.8 %11.4 %Total$866 $748 15.8 %17.0 %UbrelvyUnited States$233 $197 17.6 %17.6 %International7 6 23.3 %29.3 %Total$240 $203 17.8 %18.0 %QuliptaUnited States$172 $128 34.2 %34.2 %International21 3 >100.0 %>100.0 %Total$193 $131 47.6 %48.3 %VyalevUnited States$6 $— n/mn/mInternational57 9 >100.0 %>100.0 %Total$63 $9 >100.0 %>100.0 %DuodopaUnited States$20 $25 (19.4)%(19.4)%International76 90 (16.0)%(11.7)%Total$96 $115 (16.7)%(13.3)%Other NeuroscienceUnited States$55 $61 (9.5)%(9.5)%International4 4 (1.0)%6.5 %Total$59 $65 (8.9)%(8.4)%OncologyImbruvicaUnited States$529 $610 (13.3)%(13.3)%Collaboration revenues209 228 (8.2)%(8.2)%Total$738 $838 (11.9)%(11.9)%VenclextaUnited States$312 $281 11.0 %11.0 %International353 333 6.0 %13.4 %Total$665 $614 8.3 %12.3 %ElahereUnited States$165 $64 >100.0 %>100.0 %International14 — n/mn/mTotal$179 $64 >100.0 %>100.0 %EpkinlyCollaboration revenues$36 $22 62.1 %62.1 %International15 5 >100.0 %>100.0 %Total$51 $